by Scott Larrivee | Jun 26, 2025 | Podcast
In this episode of Talk Radioisotopes, host Scott Larrivee and guest Paul Schrimpf, Proprietor and Entrepreneur at Cyrall, unpacks what it takes to build and scale a radiopharmaceutical business. With a background spanning Accenture, Prophet, and leadership roles...
by Scott Larrivee | Jun 26, 2025 | News
The following is a copy of a press release issued by Cellectar Biosciences Partnership Provides Long-Term Supply of Iodine-125 and Actinium-225 Supports Advancement of Radiotherapeutic Pipeline and Plans to Initiate Phase 1b Clinical Trial of CLR-125 for...
by Scott Larrivee | Jun 26, 2025 | Blog
Nusano’s CEO, Chris Lowe, recently spoke to Ravi Kumar for the Connor Group’s Breakthrough Work podcast. The discussion covered: How Chris went from being CFO to leading Nusano as their CEO How Nusano technology is changing pharma, energy, and other...
by Scott Larrivee | Jun 19, 2025 | News
Alpha-emitting radioisotope expected to play an essential role in next-generation targeted cancer therapies DURHAM, N.C. and WEST VALLEY CITY, Utah – June 19, 2025 – dGenThera, Inc., a biotechnology company pioneering theranostic molecular pairs, and Nusano, a...
by Scott Larrivee | Jun 17, 2025 | News
Agreement provides Ratio access to Nusano-produced radioisotopes for oncology diagnostics and therapeutics Accelerates Ratio’s clinical pipeline with copper-64 for PET imaging and lutetium-177 and actinium-225 for targeted therapy Bolsters both companies’...
